Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Richardson

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Gynecologic Oncology|August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Breast Cancer Research : BCR|August 4, 2021
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived modelsNicole J Chew, Terry C C Lim Kam Sian, Elizabeth V Nguyen, et al.
Journal for Immunotherapy of Cancer|January 31, 2023
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primaryAtara Posner, Tharani Sivakumaran, Andrew Pattison, et al.
The Lancet. Oncology|June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trialBradley J Monk, Andrés Poveda, Ignace Vergote, et al.
JTO Clinical and Research Reports|April 20, 2026
Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational StudyAlison Hiong, Julien Robinson, Eldho Paul, et al.
JTO Clinical and Research Reports|April 20, 2026
Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality RegistryRob G Stirling, Sanuki Tissera, Jessie Zeng, et al.
Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
The Journal of Pathology|October 26, 2022
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primaryAtara Posner, Owen Wj Prall, Tharani Sivakumaran, et al.
Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Nature Medicine|July 25, 2024
Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trialAnouk E Hiensch, Johanna Depenbusch, Martina E Schmidt, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Gynecologic Oncology|August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Breast Cancer Research : BCR|August 4, 2021
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived modelsNicole J Chew, Terry C C Lim Kam Sian, Elizabeth V Nguyen, et al.
Journal for Immunotherapy of Cancer|January 31, 2023
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primaryAtara Posner, Tharani Sivakumaran, Andrew Pattison, et al.
The Lancet. Oncology|June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trialBradley J Monk, Andrés Poveda, Ignace Vergote, et al.
JTO Clinical and Research Reports|April 20, 2026
Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational StudyAlison Hiong, Julien Robinson, Eldho Paul, et al.
JTO Clinical and Research Reports|April 20, 2026
Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality RegistryRob G Stirling, Sanuki Tissera, Jessie Zeng, et al.
Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
The Journal of Pathology|October 26, 2022
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primaryAtara Posner, Owen Wj Prall, Tharani Sivakumaran, et al.
Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.
Nature Medicine|July 25, 2024
Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trialAnouk E Hiensch, Johanna Depenbusch, Martina E Schmidt, et al.
Pageof 6